{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T20:23:38Z","timestamp":1783715018056,"version":"3.55.0"},"reference-count":83,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2012,7,1]],"date-time":"2012-07-01T00:00:00Z","timestamp":1341100800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology"],"published-print":{"date-parts":[[2012,7]]},"DOI":"10.1016\/j.tripleo.2011.08.023","type":"journal-article","created":{"date-parts":[[2012,2,17]],"date-time":"2012-02-17T13:46:55Z","timestamp":1329486415000},"page":"e1-e8","source":"Crossref","is-referenced-by-count":16,"title":["Dentistry and the myasthenia gravis patient: a review of the current state of the art"],"prefix":"10.1016","volume":"114","author":[{"given":"Pavan M.","family":"Patil","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gurjap","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seema P.","family":"Patil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tripleo.2011.08.023_bib1","first-page":"404","article-title":"De anima brutorum","author":"Willis","year":"1672"},{"key":"10.1016\/j.tripleo.2011.08.023_bib2","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1754-4505.1997.tb00532.x","article-title":"Myasthenia gravis: dental treatment considerations","volume":"17","author":"Patton","year":"1997","journal-title":"Spec Care Dent"},{"key":"10.1016\/j.tripleo.2011.08.023_bib3","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1159\/000279334","article-title":"The incidence of myasthenia gravis: a systematic literature review","volume":"34","author":"McGrogan","year":"2010","journal-title":"Neuroepidemiology"},{"key":"10.1016\/j.tripleo.2011.08.023_bib4","doi-asserted-by":"crossref","first-page":"225","DOI":"10.7326\/0003-4819-81-2-225","article-title":"Myasthenia gravis","volume":"81","author":"Engel","year":"1974","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.tripleo.2011.08.023_bib5","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/0022-3913(77)90003-8","article-title":"Management of patients with myasthenia gravis who require maxillary dentures","volume":"38","author":"Bottomley","year":"1977","journal-title":"J Prosthet Dent"},{"key":"10.1016\/j.tripleo.2011.08.023_bib6","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/j.1749-6632.1966.tb45497.x","article-title":"The pathology of the thymus gland in myasthenia gravis","volume":"135","author":"Castleman","year":"1966","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.tripleo.2011.08.023_bib7","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1002\/ana.410280303","article-title":"Myasthenic thymus and thymoma are selectively enriched in acetylcholine receptor-reactive T cells","volume":"28","author":"Sommer","year":"1990","journal-title":"Ann Neurol"},{"key":"10.1016\/j.tripleo.2011.08.023_bib8","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1056\/NEJM199406233302507","article-title":"Myasthenia gravis","volume":"330","author":"Drachman","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tripleo.2011.08.023_bib9","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S1474-4422(03)00306-5","article-title":"Seronegative generalized myasthenia gravis: clinical features, antibodies and their targets","volume":"2","author":"Vincent","year":"2003","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.tripleo.2011.08.023_bib10","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/85520","article-title":"Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies","volume":"7","author":"Hoch","year":"2001","journal-title":"Nat Med"},{"key":"10.1016\/j.tripleo.2011.08.023_bib11","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1002\/ana.20341","article-title":"Acetylcholine receptors loss and postsynaptic damage in MuSK antibody-positive myasthenia gravis","volume":"57","author":"Shiraishi","year":"2005","journal-title":"Ann Neurol"},{"key":"10.1016\/j.tripleo.2011.08.023_bib12","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1002\/ana.20386","article-title":"Fewer thymic changes in MuSK antibody\u2013positive than in MuSK antibody\u2013negative MG","volume":"57","author":"Isabel","year":"2005","journal-title":"Ann Neurol"},{"key":"10.1016\/j.tripleo.2011.08.023_bib13","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1093\/brain\/awh612","article-title":"Increased expression of rapsyn in muscles prevents acetylcholine receptor loss in experimental autoimmune myasthenia gravis","volume":"128","author":"Losen","year":"2005","journal-title":"Brain"},{"key":"10.1016\/j.tripleo.2011.08.023_bib14","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/j.1600-0404.1989.tb03881.x","article-title":"Associated disorders in myasthenia gravis: autoimmune diseases and their relation to thymectomy","volume":"80","author":"Thorlacius","year":"1989","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.tripleo.2011.08.023_bib15","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jneuroim.2009.02.009","article-title":"Interleukin-10 promoter polymorphisms in myasthenia gravis","volume":"210","author":"Alseth","year":"2009","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.tripleo.2011.08.023_bib16","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/j.mehy.2007.06.044","article-title":"Prolactin may be a promising therapeutic target for myasthenia gravis: hypothesis and importance","volume":"70","author":"Yang","year":"2008","journal-title":"Med Hypothesis"},{"key":"10.1016\/j.tripleo.2011.08.023_bib17","first-page":"201","article-title":"Granzyme B: evidence for a role in the origin of myasthenia gravis","author":"Casciola-Rosen","year":"2008","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.tripleo.2011.08.023_bib18","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1111\/j.1749-6632.1981.tb33764.x","article-title":"The natural course of myasthenia gravis and effect of therapeutic measures","volume":"377","author":"Grob","year":"1981","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.tripleo.2011.08.023_bib19","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1001\/jama.293.15.1906","article-title":"Does this patient have myasthenia gravis?","volume":"293","author":"Scherer","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.tripleo.2011.08.023_bib20","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/j.1754-4505.1983.tb00115.x","article-title":"Dental management of a child with severe myasthenia gravis","volume":"3","author":"Schneider","year":"1983","journal-title":"Spec Care Dent"},{"key":"10.1016\/j.tripleo.2011.08.023_bib21","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.bjoms.2007.12.009","article-title":"An unusual primary presentation of myasthenia gravis","volume":"46","author":"Cook","year":"2008","journal-title":"Br J Oral Maxillofac Surg"},{"key":"10.1016\/j.tripleo.2011.08.023_bib22","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/0022-3913(77)90003-8","article-title":"Management of patients with myasthenia gravis who require maxillary dentures","volume":"38","author":"Bottomley","year":"1977","journal-title":"J Prosthet Dent"},{"key":"10.1016\/j.tripleo.2011.08.023_bib23","first-page":"308","article-title":"The otolaryngologist's role in myasthenia gravis","volume":"76","author":"Calcaterra","year":"1972","journal-title":"Trans Am Acad Ophthalmol Otolaryngol"},{"key":"10.1016\/j.tripleo.2011.08.023_bib24","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1212\/WNL.48.5.1253","article-title":"Myasthenic crisis: clinical features, mortality, complications, and risk factors for prolonged intubation","volume":"48","author":"Thomas","year":"1997","journal-title":"Neurology"},{"key":"10.1016\/j.tripleo.2011.08.023_bib25","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1097\/00003246-199707000-00027","article-title":"Therapy of myasthenic crisis","volume":"25","author":"Berrouschot","year":"1997","journal-title":"Crit Care Med"},{"key":"10.1016\/j.tripleo.2011.08.023_bib26","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1212\/WNL.55.1.16","article-title":"Myasthenia gravis: recommendations for clinical research standards","volume":"55","author":"Jaretzki","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.tripleo.2011.08.023_bib27","first-page":"1170","article-title":"Oxford textbook of medicine","author":"Warrell","year":"2003"},{"key":"10.1016\/j.tripleo.2011.08.023_bib28","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/1471-2474-5-42","article-title":"Myasthenia gravis and pregnancy: clinical implications and neonatal outcome","volume":"5","author":"T\u00e9llez-Zenteno","year":"2004","journal-title":"BMC Musculoskelet Disord"},{"issue":"950","key":"10.1016\/j.tripleo.2011.08.023_bib29","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1136\/pgmj.2004.018903","article-title":"Update on myasthenia gravis","volume":"80","author":"Thanvi","year":"2004","journal-title":"Post Grad Med J"},{"key":"10.1016\/j.tripleo.2011.08.023_bib30","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1111\/j.1469-8749.2008.02038.x","article-title":"Neurophysiological strategies for the diagnosis of disorders of the neuromuscular junction in children 3","volume":"50","author":"Pitt","year":"2008","journal-title":"Dev Med Child Neurol"},{"key":"10.1016\/j.tripleo.2011.08.023_bib31","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.clinph.2009.12.017","article-title":"Diagnostic value of double-step nerve stimulation test in patients with myasthenia gravis","volume":"121","author":"Temu\u00e7in","year":"2010","journal-title":"Clin Neurophysiol"},{"key":"10.1016\/j.tripleo.2011.08.023_bib32","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.1016\/j.ophtha.2009.04.039","article-title":"The ice pack test in the differential diagnosis of myasthenic diplopia","volume":"116","author":"Chatzistefanou","year":"2009","journal-title":"Ophthalmology"},{"key":"10.1016\/j.tripleo.2011.08.023_bib33","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1510\/icvts.2004.097246","article-title":"CT and myasthenia gravis: correlation between mediastinal imaging and histopathological findings","volume":"4","author":"de Kraker","year":"2005","journal-title":"Interact Cardiovasc Thorac Surg"},{"key":"10.1016\/j.tripleo.2011.08.023_bib34","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/mus.20403","article-title":"Pulmonary function tests and blood gases in worsening myasthenia gravis","volume":"32","author":"Thieben","year":"2005","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.tripleo.2011.08.023_bib35","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1093\/brain\/awh612","article-title":"Increased expression of rapsyn in muscles prevents acetylcholine receptor loss in experimental autoimmune myasthenia gravis","volume":"128","author":"Losen","year":"2005","journal-title":"Brain"},{"key":"10.1016\/j.tripleo.2011.08.023_bib36","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S0003-9969(02)00014-6","article-title":"Masticatory performance in patients with myasthenia gravis","volume":"47","author":"Weijnen","year":"2002","journal-title":"Arch Oral Biol"},{"key":"10.1016\/j.tripleo.2011.08.023_bib37","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/S0901-5027(00)80058-2","article-title":"Myasthenia gravis associated with reduced masticatory function","volume":"29","author":"Sasakura","year":"2000","journal-title":"Int J Oral Maxillofac Surg"},{"key":"10.1016\/j.tripleo.2011.08.023_bib38","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/j.1754-4505.1981.tb01219.x","article-title":"Electromyographic activity of masticatory muscles in patients with progressive muscular dystrophy (Duchenne type): between integrated electromyographic activity and biting force","volume":"1","author":"Hamada","year":"1981","journal-title":"Spec Care Dent"},{"key":"10.1016\/j.tripleo.2011.08.023_bib39","doi-asserted-by":"crossref","first-page":"244","DOI":"10.2334\/josnusd1959.30.244","article-title":"Relationship between the values of masticatory efficiency and biting pressure in children with cerebral palsy\u2014inter-relationship between the maximum biting pressure, chewing cycle and the value of masticatory efficiency","volume":"30","author":"Nakajima","year":"1988","journal-title":"J Nihon Univ Sch Dent"},{"key":"10.1016\/j.tripleo.2011.08.023_bib40","series-title":"Myasthenia gravis","first-page":"13","article-title":"Clinical aspects","author":"Oosterhuis","year":"1993"},{"key":"10.1016\/j.tripleo.2011.08.023_bib41","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0344-0338(87)80147-4","article-title":"Histopathology of different types of atrophy of the human tongue","volume":"182","author":"B\u00e4ssler","year":"1987","journal-title":"Pathol Res Pract"},{"key":"10.1016\/j.tripleo.2011.08.023_bib42","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jns.2010.12.009","article-title":"Proton magnetic resonance spectroscopy of the intrinsic tongue muscles in patients with myasthenia gravis with different autoantibodies","volume":"302","author":"Lavrnic","year":"2011","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.tripleo.2011.08.023_bib43","first-page":"30","article-title":"Current concepts in the surgical treatment of patients with myasthenia gravis","volume":"39","author":"Gallagher","year":"1981","journal-title":"J Oral Surg"},{"key":"10.1016\/j.tripleo.2011.08.023_bib44","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1016\/S0190-9622(08)81260-1","article-title":"Chronic mucocutaneous candidiasis","volume":"31","author":"Kikpatrick","year":"1994","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.tripleo.2011.08.023_bib45","doi-asserted-by":"crossref","first-page":"476","DOI":"10.14219\/jada.archive.1982.0357","article-title":"Glucocorticoids in dentistry","volume":"105","author":"Bahn","year":"1982","journal-title":"J Am Dent Assoc"},{"key":"10.1016\/j.tripleo.2011.08.023_bib46","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.clineuro.2010.06.018","article-title":"Benefits from sustained release pyridostigmine bromide in myasthenia gravis: results of a prospective multicenter open-label trial","volume":"112","author":"Sieba","year":"2010","journal-title":"Clin Neurol Neurosurg"},{"issue":"Suppl","key":"10.1016\/j.tripleo.2011.08.023_bib47","first-page":"81","article-title":"Anti-sense approach to anticholinesterase therapeutics","volume":"2","author":"Soreq","year":"2000","journal-title":"Isr Med Assoc J"},{"key":"10.1016\/j.tripleo.2011.08.023_bib48","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1097\/00000658-193910000-00005","article-title":"Myasthenia gravis and tumors of the thymic region: report of a case in which the tumor was removed","volume":"110","author":"Blalock","year":"1939","journal-title":"Ann Surg"},{"key":"10.1016\/j.tripleo.2011.08.023_bib49","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1001\/archneur.1971.00490050019001","article-title":"Thymectomy in juvenile myasthenia gravis","volume":"25","author":"Seybold","year":"1971","journal-title":"Arch Neurol"},{"key":"10.1016\/j.tripleo.2011.08.023_bib50","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1097\/00000658-199910000-00011","article-title":"Results of transcervical thymectomy for myasthenia gravis in 100 consecutive patients","volume":"230","author":"Calhoun","year":"1999","journal-title":"Ann Surg"},{"key":"10.1016\/j.tripleo.2011.08.023_bib51","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/0896-8411(91)90018-8","article-title":"Antiacetylcholine receptor antibodies decrease after thymectomy in patients with myasthenia gravis: clinical correlations","volume":"4","author":"Kuks","year":"1991","journal-title":"J Autoimmun"},{"key":"10.1016\/j.tripleo.2011.08.023_bib52","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1111\/j.1749-6632.1987.tb51325.x","article-title":"Long-term corticosteroid treatment of myasthenia gravis","volume":"505","author":"Johns","year":"1987","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.tripleo.2011.08.023_bib53","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1056\/NEJM197401102900204","article-title":"Gradually increasing doses of prednisone in myasthenia gravis: reducing the hazards of treatment","volume":"290","author":"Seybold","year":"1974","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tripleo.2011.08.023_bib54","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/j.1749-6632.1993.tb22937.x","article-title":"A clinical therapeutic trial of cyclosporine in myasthenia gravis","volume":"681","author":"Tindall","year":"1993","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.tripleo.2011.08.023_bib55","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1002\/mus.20030","article-title":"Clinical evaluation and management of myasthenia gravis","volume":"29","author":"Keesey","year":"2004","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.tripleo.2011.08.023_bib56","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1097\/00007691-200404000-00018","article-title":"Pharmacogenetics of thiopurine S-methyltransferase and thiopurine therapy","volume":"26","author":"Evans","year":"2004","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.tripleo.2011.08.023_bib58","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/ana.10400","article-title":"Treatment of refractory myasthenia: \u201crebooting\u201d with high-dose cyclophosphamide","volume":"53","author":"Drachman","year":"2003","journal-title":"Ann Neurol"},{"key":"10.1016\/j.tripleo.2011.08.023_bib59","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/mus.10018","article-title":"Successful treatment of myasthenia gravis with tacrolimus","volume":"25","author":"Evoli","year":"2002","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.tripleo.2011.08.023_bib60","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1159\/000050768","article-title":"Mycophenolate mofetil in the therapy of severe myasthenia gravis","volume":"46","author":"Schneider","year":"2001","journal-title":"Eur Neurol"},{"key":"10.1016\/j.tripleo.2011.08.023_bib61","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1212\/WNL.56.1.97","article-title":"Mycophenolate mofetil for myasthenia gravis: an open-label pilot study","volume":"56","author":"Ciafaloni","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.tripleo.2011.08.023_bib62","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1212\/WNL.56.1.94","article-title":"Mycophenolate mofetil: a safe and promising immunosuppressant in neuromuscular diseases","volume":"56","author":"Chaudhry","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.tripleo.2011.08.023_bib63","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1196\/annals.1254.064","article-title":"Mycophenolate mofetil for myasthenia gravis: a double-blind, placebo-controlled pilot study","volume":"998","author":"Meriggioli","year":"2003","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.tripleo.2011.08.023_bib64","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1196\/annals.1405.000","article-title":"Tacrolimus for myasthenia gravis: a clinical study of 212 patients","volume":"1132","author":"Ponseti","year":"2008","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.tripleo.2011.08.023_bib65","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jns.2010.09.033","article-title":"Five-year follow-up with low-dose tacrolimus in patients with myasthenia gravis","volume":"300","author":"Minami","year":"2011","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.tripleo.2011.08.023_bib66","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1185\/030079904125004385","article-title":"Low-dose tacrolimus treatment in thymectomised and steroid-dependent myasthenia gravis","volume":"20","author":"Kawaguchi","year":"2004","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.tripleo.2011.08.023_bib67","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1067\/S0022-3476(03)00300-7","article-title":"Successful treatment of refractory myasthenia gravis using rituximab: a pediatric case report","volume":"143","author":"Wylam","year":"2003","journal-title":"J Pediatr"},{"key":"10.1016\/j.tripleo.2011.08.023_bib68","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1212\/WNL.55.7.1062-a","article-title":"Rituximab for myasthenia gravis developing after bone marrow transplant","volume":"55","author":"Zaja","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.tripleo.2011.08.023_bib69","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/j.1468-1331.2008.02399.x","article-title":"Successful treatment of refractory generalized myasthenia gravis with rituximab","volume":"16","author":"Lebrun","year":"2009","journal-title":"Eur J Neurol"},{"issue":"4","key":"10.1016\/j.tripleo.2011.08.023_bib70","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD002275","article-title":"Plasma exchange for myasthenia gravis","author":"Gajdos","year":"2002","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.tripleo.2011.08.023_bib71","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1111\/j.1744-9987.2009.00684.x","article-title":"Periodic therapeutic plasma exchange in patients with moderate to severe chronic myasthenia gravis nonresponsive to immunosuppressive agents: an eight year follow-up","volume":"13","author":"Triantafyllou","year":"2009","journal-title":"Ther Apher Dial"},{"key":"10.1016\/j.tripleo.2011.08.023_bib72","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1056\/NEJMra993360","article-title":"Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin","volume":"345","author":"Kazatchkine","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tripleo.2011.08.023_bib73","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1046\/j.1526-0968.2003.00008.x","article-title":"Adsorption column for myasthenia gravis treatment: medisorba MG-50","volume":"7","author":"Nakaji","year":"2003","journal-title":"Ther Apher Dial"},{"key":"10.1016\/j.tripleo.2011.08.023_bib74","doi-asserted-by":"crossref","first-page":"419520","DOI":"10.1155\/2010\/419520","article-title":"Extracorporeal immunoglobulin elimination for the treatment of severe myasthenia gravis","volume":"2010","author":"Blaha","year":"2010","journal-title":"J Biomed Biotechnol"},{"key":"10.1016\/j.tripleo.2011.08.023_bib75","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jneuroim.2008.12.005","article-title":"Administration of bone marrow stromal cells ameliorates experimental autoimmune myasthenia gravis by altering the balance of TH1\/TH2\/TH17\/Treg cell subsets through the secretion of TGF-beta","volume":"207","author":"Kong","year":"2009","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.tripleo.2011.08.023_bib76","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1196\/annals.1254.068","article-title":"Specific immunotherapy of experimental myasthenia by genetically engineered APCs: the \u201cguided missile\u201d strategy","volume":"998","author":"Drachman","year":"2003","journal-title":"Ann N Y Acad Sci"},{"issue":"Suppl 2","key":"10.1016\/j.tripleo.2011.08.023_bib77","doi-asserted-by":"crossref","first-page":"14586","DOI":"10.1073\/pnas.0404826101","article-title":"Therapeutic vaccines in autoimmunity","volume":"101","author":"Sela","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.tripleo.2011.08.023_bib78","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1196\/annals.1254.070","article-title":"Suppression of EAMG in Lewis rats by IL-10-exposed dendritic cells","volume":"998","author":"Link","year":"2003","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.tripleo.2011.08.023_bib79","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0014-5793(03)00745-2","article-title":"Prevention of passively transferred experimental autoimmune myasthenia gravis by an in vitro selected RNA aptamer","volume":"548","author":"Hwang","year":"2003","journal-title":"FEBS Lett"},{"key":"10.1016\/j.tripleo.2011.08.023_bib80","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1001\/archneur.1986.00520030045010","article-title":"Ampicillin may aggravate clinical and experimental myasthenia gravis","volume":"43","author":"Argov","year":"1986","journal-title":"Arch Neurol"},{"key":"10.1016\/j.tripleo.2011.08.023_bib81","first-page":"286","article-title":"Exacerbation of myasthenia gravis by pefloxacin","volume":"151","author":"Vial","year":"1995","journal-title":"Rev Neurol Paris"},{"key":"10.1016\/j.tripleo.2011.08.023_bib82","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1212\/WNL.50.3.804","article-title":"Fluoroquinolone antibiotics block neuromuscular transmission","volume":"50","author":"Sieb","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/j.tripleo.2011.08.023_bib85","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/0022-3913(93)90111-Z","article-title":"Masseter muscle fatigue during sustained clenching in subjects with complete dentures, Implant supported prostheses, and natural teeth","volume":"69","author":"Jacobs","year":"1993","journal-title":"J Prosthet Dent"},{"key":"10.1016\/j.tripleo.2011.08.023_bib86","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/j.1365-2842.1979.tb00399.x","article-title":"Prosthodontic failures in patients with systemic disorders","volume":"6","author":"Langer","year":"1979","journal-title":"J Oral Rehabil"}],"container-title":["Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079210411006214?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079210411006214?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,23]],"date-time":"2019-06-23T22:17:46Z","timestamp":1561328266000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1079210411006214"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7]]},"references-count":83,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,7]]}},"alternative-id":["S1079210411006214"],"URL":"https:\/\/doi.org\/10.1016\/j.tripleo.2011.08.023","relation":{},"ISSN":["2212-4403"],"issn-type":[{"value":"2212-4403","type":"print"}],"subject":[],"published":{"date-parts":[[2012,7]]}}}